Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03690388 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT03690388 · ClinicalTrials.gov record · last posted 2025-09-25

A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy

StatusActive, Not Recruiting
PhasePhase 3
SponsorExelixis
Started2018-10-05
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The objective of this study is to evaluate the effect of cabozantinib compared with placebo on progression free survival (PFS) and objective response rate (ORR) in subjects with Radioiodine-Refractory Differentiated Thyroid Cancer (DTC) who have progressed after prior vascular endothelial growth factor receptor (VEGFR)-Targeted therapy.

Amendment record 37 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 37 times since 2018-09-27; most recent amendment 2025-09-12. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2021-06-02
Status change Recruiting→Active, Not Recruitingv29
2018-10-10
Status change Not Yet Recruiting→Recruitingv1
Trial Details
NCT Number NCT03690388
Lead Sponsor Exelixis
Collaborators: Ipsen
Conditions Differentiated Thyroid Cancer
Enrollment 187 participants
Start Date 2018-10-05
Primary Completion 2020-08-19 (estimated)
Study Completion 2026-07-31 (estimated)
Updated on ClinicalTrials.gov 2025-09-25